Pancreatic adenocarcinomas without KRAS, TP53, CDKN2A and SMAD4 mutations and CDKN2A/CDKN2B copy number alterations: a review of the genomic landscape to unveil therapeutic avenues
Radiotherapy, lymphopenia and improving the outcome for glioblastoma: a narrative review
Narrative review: current management and novel targeted therapies in intrahepatic cholangiocarcinoma
Sentinel lymph node biopsy following neoadjuvant chemotherapy: an evidence-based review and recommendations for current practice
Interviews with Outstanding Guest Editors1
1. The series “Interviews with Outstanding Guest Editors” was commissioned by the editorial office, Chinese Clinical Oncology without any funding or sponsorship.